{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T19:11:08Z","timestamp":1778094668307,"version":"3.51.4"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"vor","delay-in-days":14,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EJNMMI Res"],"DOI":"10.1186\/s13550-026-01433-9","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T20:17:40Z","timestamp":1776889060000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Dosimetry of [177Lu]Lu-PSMA therapy in a hemodialysis patient: a case study"],"prefix":"10.1186","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0363-2471","authenticated-orcid":false,"given":"Arjan D.","family":"Hendriks","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alferso C.","family":"Abrahams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rob","family":"van Rooij","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fleur G. M.","family":"Verkaar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martijn","family":"Dingemans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John L. M.","family":"Bemelmans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kwok Wai","family":"Mui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hugo W. A. M.","family":"de Jong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marnix G. E. H.","family":"Lam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,22]]},"reference":[{"issue":"4","key":"1433_CR1","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1053\/j.semnuclmed.2024.02.003","volume":"54","author":"A Al-Ibraheem","year":"2024","unstructured":"Al-Ibraheem A, Zimmermann R, Abdlkadir AS, Herrmann K. Radiotheranostics global market and future developments. Semin Nucl Med. 2024;54(4):622\u201333. https:\/\/doi.org\/10.1053\/j.semnuclmed.2024.02.003.","journal-title":"Semin Nucl Med"},{"issue":"7","key":"1433_CR2","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1007\/s00259-023-06139-x","volume":"50","author":"L Flegar","year":"2023","unstructured":"Flegar L, Thoduka SG, Librizzi D, Luster M, Zacharis A, Heers H, et al. Adoption of Lutetium-177 PSMA radioligand therapy for metastatic castration resistant prostate cancer: a total population analysis in Germany from 2016 to 2020. Eur J Nucl Med Mol Imaging. 2023;50(7):2188\u201395. https:\/\/doi.org\/10.1007\/s00259-023-06139-x.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"9","key":"1433_CR3","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.2967\/jnumed.124.267951","volume":"65","author":"A Poschenrieder","year":"2024","unstructured":"Poschenrieder A, Taleska J, Schaetz L. 177Lu-PSMA (R)evolution in cancer care: is it really happening? J Nucl Med. 2024;65(9):1340\u20132. https:\/\/doi.org\/10.2967\/jnumed.124.267951.","journal-title":"J Nucl Med"},{"issue":"17","key":"1433_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27175730","volume":"27","author":"M Sekhoacha","year":"2022","unstructured":"Sekhoacha M, Riet K, Motloung P, Gumenku L, Adegoke A, Mashele S. Prostate cancer review: genetics, diagnosis, treatment options, and alternative approaches. Molecules. 2022;27(17):5730. https:\/\/doi.org\/10.3390\/molecules27175730.","journal-title":"Molecules"},{"key":"1433_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1246881","volume":"10","author":"G Chen","year":"2023","unstructured":"Chen G, Lu Z, Jiang H, Afshar-Oromieh A, Rominger A, Shi K, et al. Lu-177-PSMA dosimetry for kidneys and tumors based on SPECT images at two imaging time points. Front Med (Lausanne). 2023;10:1246881. https:\/\/doi.org\/10.3389\/fmed.2023.1246881.","journal-title":"Front Med (Lausanne)"},{"issue":"12","key":"1433_CR6","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385(12):1091\u2013103. https:\/\/doi.org\/10.1056\/NEJMoa2107322.","journal-title":"N Engl J Med"},{"issue":"9","key":"1433_CR7","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.1007\/s00259-023-06255-8","volume":"50","author":"C Kratochwil","year":"2023","unstructured":"Kratochwil C, Fendler WP, Eiber M, Hofman MS, Emmett L, Calais J, et al. Joint EANM\/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT). Eur J Nucl Med Mol Imaging. 2023;50(9):2830\u201345. https:\/\/doi.org\/10.1007\/s00259-023-06255-8.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"12","key":"1433_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13123095","volume":"13","author":"F Rosar","year":"2021","unstructured":"Rosar F, Kochems N, Bartholom\u00e4 M, Maus S, Stemler T, Linxweiler J, et al. Renal safety of [177Lu]Lu-PSMA-617 radioligand therapy in patients with compromised baseline kidney function. Cancers (Basel). 2021;13(12):3095. https:\/\/doi.org\/10.3390\/cancers13123095.","journal-title":"Cancers (Basel)"},{"issue":"6","key":"1433_CR9","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1093\/ckj\/sfz101","volume":"13","author":"M Gallyamov","year":"2020","unstructured":"Gallyamov M, Meyrick D, Barley J, Lenzo N. Renal outcomes of radioligand therapy: experience of 177lutetium-prostate-specific membrane antigen ligand therapy in metastatic castrate-resistant prostate cancer. Clin Kidney J. 2020;13(6):1049\u201355. https:\/\/doi.org\/10.1093\/ckj\/sfz101.","journal-title":"Clin Kidney J"},{"issue":"9","key":"1433_CR10","doi-asserted-by":"publisher","first-page":"3135","DOI":"10.1007\/s00259-025-07125-1","volume":"52","author":"E Topal","year":"2025","unstructured":"Topal E, Kovan B, \u0130ribas A, Kuyumcu S, Basaran M, Mal\u00e7ok Demirta\u015f A, et al. Impact of extended [177Lu] Lu-PSMA-617 therapy on absorbed kidney dose and CKD-EPI values: how long can therapy be safely continued? Eur J Nucl Med Mol Imaging. 2025;52(9):3135\u201344. https:\/\/doi.org\/10.1007\/s00259-025-07125-1.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"1433_CR11","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/j.radcr.2024.10.084","volume":"20","author":"YY Huang","year":"2025","unstructured":"Huang YY, Lin TC, Yang SH, Lai LS, Hung LM, Li MH, et al. Radiation safety and dialysate analysis in hemodialysis following Lu-177-PSMA-617 therapy: a case report. Radiol Case Rep. 2025;20(1):805\u20139. https:\/\/doi.org\/10.1016\/j.radcr.2024.10.084.","journal-title":"Radiol Case Rep"},{"key":"1433_CR12","doi-asserted-by":"publisher","unstructured":"Kneer H, Kull T, Beer AJ, Prasad V. Planung und Organisation einer Radiojod- oder Lutetium-Therapie bei dialysepflichtigen Patienten. In Leipzig; 2022. p. s-0042-1746143. https:\/\/doi.org\/10.1055\/s-0042-1746143","DOI":"10.1055\/s-0042-1746143"},{"issue":"7","key":"1433_CR13","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.2967\/jnumed.115.168443","volume":"57","author":"RP Baum","year":"2016","unstructured":"Baum RP, Kulkarni HR, Schuchardt C, Singh A, Wirtz M, Wiessalla S, et al. 177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy. J Nucl Med. 2016;57(7):1006\u201313. https:\/\/doi.org\/10.2967\/jnumed.115.168443.","journal-title":"J Nucl Med"},{"issue":"8","key":"1433_CR14","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.2967\/jnumed.115.171397","volume":"57","author":"C Kratochwil","year":"2016","unstructured":"Kratochwil C, Giesel FL, Stefanova M, Bene\u0161ov\u00e1 M, Bronzel M, Afshar-Oromieh A, et al. PSMA-targeted radionuclide therapy of metastatic castration-resistant prostate cancer with 177Lu-labeled PSMA-617. J Nucl Med. 2016;57(8):1170\u20136. https:\/\/doi.org\/10.2967\/jnumed.115.171397.","journal-title":"J Nucl Med"},{"issue":"1","key":"1433_CR15","doi-asserted-by":"publisher","first-page":"71","DOI":"10.2967\/jnumed.123.265448","volume":"65","author":"K Herrmann","year":"2024","unstructured":"Herrmann K, Rahbar K, Eiber M, Sparks R, Baca N, Krause BJ, et al. Renal and multiorgan safety of 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer in the VISION dosimetry substudy. J Nucl Med. 2024;65(1):71\u20138. https:\/\/doi.org\/10.2967\/jnumed.123.265448.","journal-title":"J Nucl Med"},{"issue":"2","key":"1433_CR16","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1007\/s00259-021-05471-4","volume":"49","author":"SMB Peters","year":"2022","unstructured":"Peters SMB, Priv\u00e9 BM, de Bakker M, de Lange F, Jentzen W, Eek A, et al. Intra-therapeutic dosimetry of [177Lu]Lu-PSMA-617 in low-volume hormone-sensitive metastatic prostate cancer patients and correlation with treatment outcome. Eur J Nucl Med Mol Imaging. 2022;49(2):460\u20139. https:\/\/doi.org\/10.1007\/s00259-021-05471-4.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"1433_CR17","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/ki.1975.98","volume":"8","author":"J Milutinovic","year":"1975","unstructured":"Milutinovic J, Cutler RE, Hoover P, Meijsen B, Scribner BH. Measurement of residual glomerular filtration rate in the patient receiving repetitive hemodialysis. Kidney Int. 1975;8(3):185\u201390. https:\/\/doi.org\/10.1038\/ki.1975.98.","journal-title":"Kidney Int"},{"issue":"5","key":"1433_CR18","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1681\/ASN.V75745","volume":"7","author":"RW van Olden","year":"1996","unstructured":"van Olden RW, Krediet RT, Struijk DG, Arisz L. Measurement of residual renal function in patients treated with continuous ambulatory peritoneal dialysis. J Am Soc Nephrol. 1996;7(5):745\u201350. https:\/\/doi.org\/10.1681\/ASN.V75745.","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"1433_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s13550-018-0386-4","volume":"8","author":"J Kurth","year":"2018","unstructured":"Kurth J, Krause BJ, Schwarzenb\u00f6ck SM, Stegger L, Sch\u00e4fers M, Rahbar K. External radiation exposure, excretion, and effective half-life in 177Lu-PSMA-targeted therapies. EJNMMI Res. 2018;8(1):32. https:\/\/doi.org\/10.1186\/s13550-018-0386-4.","journal-title":"EJNMMI Res"},{"issue":"8","key":"1433_CR20","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.2967\/jnumed.121.262713","volume":"63","author":"C Schuchardt","year":"2022","unstructured":"Schuchardt C, Zhang J, Kulkarni HR, Chen X, M\u00fcller D, Baum RP. Prostate-Specific membrane antigen radioligand therapy using 177Lu-PSMA I&T and 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer: comparison of safety, biodistribution, and dosimetry. J Nucl Med. 2022;63(8):1199\u2013207. https:\/\/doi.org\/10.2967\/jnumed.121.262713.","journal-title":"J Nucl Med"},{"issue":"3","key":"1433_CR21","doi-asserted-by":"publisher","first-page":"477","DOI":"10.2967\/jnumed.108.056036","volume":"50","author":"WE Bolch","year":"2009","unstructured":"Bolch WE, Eckerman KF, Sgouros G, Thomas SR. MIRD pamphlet 21: a generalized schema for radiopharmaceutical dosimetry\u2013standardization of nomenclature. J Nucl Med. 2009;50(3):477\u201384. https:\/\/doi.org\/10.2967\/jnumed.108.056036.","journal-title":"J Nucl Med"},{"issue":"6","key":"1433_CR22","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1007\/s00259-022-05727-7","volume":"49","author":"K Sj\u00f6green Gleisner","year":"2022","unstructured":"Sj\u00f6green Gleisner K, Chouin N, Gabina PM, Cicone F, Gnesin S, Stokke C, et al. EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands. Eur J Nucl Med Mol Imaging. 2022;49(6):1778\u2013809. https:\/\/doi.org\/10.1007\/s00259-022-05727-7.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"1433_CR23","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1007\/s00259-010-1422-4","volume":"37","author":"C Hindorf","year":"2010","unstructured":"Hindorf C, Glatting G, Chiesa C, Lind\u00e9n O, Flux G, EANM Dosimetry Committee. EANM Dosimetry Committee guidelines for bone marrow and whole-body dosimetry. Eur J Nucl Med Mol Imaging. 2010;37(6):1238\u201350. https:\/\/doi.org\/10.1007\/s00259-010-1422-4.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"1433_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s13550-018-0427-z","volume":"8","author":"A Gosewisch","year":"2018","unstructured":"Gosewisch A, Delker A, Tattenberg S, Ilhan H, Todica A, Brosch J, et al. Patient-specific image-based bone marrow dosimetry in Lu-177-[DOTA0,Tyr3]-Octreotate and Lu-177-DKFZ-PSMA-617 therapy: investigation of a new hybrid image approach. EJNMMI Res. 2018;8(1):76. https:\/\/doi.org\/10.1186\/s13550-018-0427-z.","journal-title":"EJNMMI Res"},{"issue":"7","key":"1433_CR25","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.2967\/jnumed.122.264225","volume":"64","author":"AL Kesner","year":"2023","unstructured":"Kesner AL, Carter LM, Ramos JCO, Lafontaine D, Olguin EA, Brown JL, et al. MIRD Pamphlet No. 28, Part 1: MIRDcalc-A Software Tool for Medical Internal Radiation Dosimetry. J Nucl Med. 2023;64(7):1117\u201324. https:\/\/doi.org\/10.2967\/jnumed.122.264225.","journal-title":"J Nucl Med"},{"issue":"8","key":"1433_CR26","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.2967\/jnumed.124.267452","volume":"65","author":"Z Ells","year":"2024","unstructured":"Ells Z, Grogan TR, Czernin J, Dahlbom M, Calais J. Dosimetry of [177Lu]Lu-PSMA-targeted radiopharmaceutical therapies in patients with prostate cancer: a comparative systematic review and metaanalysis. J Nucl Med. 2024;65(8):1264\u201371. https:\/\/doi.org\/10.2967\/jnumed.124.267452.","journal-title":"J Nucl Med"},{"issue":"11","key":"1433_CR27","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1007\/s12149-021-01659-8","volume":"35","author":"K Chatachot","year":"2021","unstructured":"Chatachot K, Shiratori S, Chaiwatanarat T, Khamwan K. Patient dosimetry of 177Lu-PSMA I&T in metastatic prostate cancer treatment: the experience in Thailand. Ann Nucl Med. 2021;35(11):1193\u2013202. https:\/\/doi.org\/10.1007\/s12149-021-01659-8.","journal-title":"Ann Nucl Med"},{"key":"1433_CR28","doi-asserted-by":"publisher","first-page":"1483953","DOI":"10.3389\/fonc.2024.1483953","volume":"14","author":"AR Hansen","year":"2024","unstructured":"Hansen AR, Probst S, Beauregard JM, Viglianti BL, Michalski JM, Tagawa ST, et al. Initial clinical experience with [177Lu]Lu-PNT2002 radioligand therapy in metastatic castration-resistant prostate cancer: dosimetry, safety, and efficacy from the lead-in cohort of the SPLASH trial. Front Oncol. 2024;14:1483953. https:\/\/doi.org\/10.3389\/fonc.2024.1483953.","journal-title":"Front Oncol"},{"key":"1433_CR29","doi-asserted-by":"crossref","unstructured":"ICRP. 1984. Nonstochastic effects of ionizing radiation. Oxford Frankfurt a.M.: Pergamon Pr; 1984. 33 p. (Annals of the ICRP; vol. 14 (3)).","DOI":"10.1016\/0146-6453(84)90003-4"},{"issue":"12","key":"1433_CR30","doi-asserted-by":"publisher","first-page":"2536","DOI":"10.1007\/s00259-019-04485-3","volume":"46","author":"C Kratochwil","year":"2019","unstructured":"Kratochwil C, Fendler WP, Eiber M, Baum R, Bozkurt MF, Czernin J, et al. EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT). Eur J Nucl Med Mol Imaging. 2019;46(12):2536\u201344. https:\/\/doi.org\/10.1007\/s00259-019-04485-3.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"1433_CR31","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1089\/108497802760363222","volume":"17","author":"JA O\u2019Donoghue","year":"2002","unstructured":"O\u2019Donoghue JA, Baidoo N, Deland D, Welt S, Divgi CR, Sgouros G. Hematologic toxicity in radioimmunotherapy: dose-response relationships for I-131 labeled antibody therapy. Cancer Biother Radiopharm. 2002;17(4):435\u201343. https:\/\/doi.org\/10.1089\/108497802760363222.","journal-title":"Cancer Biother Radiopharm"},{"issue":"10","key":"1433_CR32","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.2967\/jnumed.123.265577","volume":"64","author":"L Mercolli","year":"2023","unstructured":"Mercolli L, Mingels C, Manzini G, Cumming P, Zeimpekis K, Xue S, et al. [177Lu]Lu-PSMA-617 therapy in a patient with chronic kidney disease. J Nucl Med. 2023;64(10):1570\u20133. https:\/\/doi.org\/10.2967\/jnumed.123.265577.","journal-title":"J Nucl Med"},{"issue":"3","key":"1433_CR33","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1055\/a-2224-9536","volume":"63","author":"K Glass","year":"2024","unstructured":"Glass K, Hering AH, Heinzel A. Dosimetry in a patient with peritoneal dialysis treated with [177Lu]Lu-PSMA-617. Nuklearmedizin. 2024;63(3):224\u20136. https:\/\/doi.org\/10.1055\/a-2224-9536.","journal-title":"Nuklearmedizin"},{"key":"1433_CR34","unstructured":"Lin TC, Yang SH, Lai LS, Hung LM, Yang CL, Li MH et al. Biological effective half-life of 177Lu-PSMA-617 therapy in patient undergoing hemodialysis \u2013 A Case Report. J Nucl Med. 2023 June 1;64(supplement 1):T30."},{"issue":"11","key":"1433_CR35","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.2967\/jnumed.118.223149","volume":"60","author":"J Zhang","year":"2019","unstructured":"Zhang J, Kulkarni HR, Singh A, Schuchardt C, Niepsch K, Langbein T, et al. 177Lu-PSMA-617 radioligand therapy in metastatic castration-resistant prostate cancer patients with a single functioning kidney. J Nucl Med. 2019;60(11):1579\u201386. https:\/\/doi.org\/10.2967\/jnumed.118.223149.","journal-title":"J Nucl Med"},{"issue":"2","key":"1433_CR36","doi-asserted-by":"publisher","first-page":"e213","DOI":"10.1097\/RLU.0000000000003912","volume":"47","author":"S Usmani","year":"2022","unstructured":"Usmani S, Al Kandari F, Alrekhais I, Khalaf N, Ahmed S. Excellent response to adapted low-dose 177Lu-PSMA-617 PSMA therapy in renal compromise patient. Clin Nucl Med. 2022;47(2):e213-4. https:\/\/doi.org\/10.1097\/RLU.0000000000003912.","journal-title":"Clin Nucl Med"},{"key":"1433_CR37","doi-asserted-by":"publisher","DOI":"10.1177\/17588359231177018","volume":"15","author":"DEK Sutherland","year":"2023","unstructured":"Sutherland DEK, Kashyap R, Jackson P, Buteau JP, Murphy DG, Kelly B, et al. Safety of lutetium-177 prostate-specific membrane antigen-617 (PSMA-617) radioligand therapy in the setting of severe renal impairment: a case report and literature review. Ther Adv Med Oncol. 2023;15:17588359231177018. https:\/\/doi.org\/10.1177\/17588359231177018.","journal-title":"Ther Adv Med Oncol"},{"issue":"6","key":"1433_CR38","doi-asserted-by":"publisher","DOI":"10.1111\/jne.13393","volume":"36","author":"NA Trikalinos","year":"2024","unstructured":"Trikalinos NA, Kim H, Vijayan A, Amurao M, Prasad V. Use of approved Lu-177 radiopharmaceuticals in patients with end-stage renal disease: A review of the literature and proposed treatment algorithm. J Neuroendocrinol. 2024;36(6):e13393. https:\/\/doi.org\/10.1111\/jne.13393.","journal-title":"J Neuroendocrinol"},{"key":"1433_CR39","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0000000000006112","author":"K Al Riyami","year":"2025","unstructured":"Al Riyami K, Jain A, Al Busaidi A, Al Balushi A, Rasheed R, Usmani S. Super Responder of 177Lu-PSMA-617 PSMA Therapy in Patient With End-Stage Renal Disease on Hemodialysis. Clin Nucl Med. 2025. https:\/\/doi.org\/10.1097\/RLU.0000000000006112.","journal-title":"Clin Nucl Med"},{"issue":"6","key":"1433_CR40","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1097\/RLU.0000000000002508","volume":"44","author":"G Norouzi","year":"2019","unstructured":"Norouzi G, Aghdam RA, Hashemifard H, Pirayesh E. Excellent response to lower dose of 177Lu-PSMA-617 in a metastatic castration-resistant prostate cancer patient with a transplanted kidney. Clin Nucl Med. 2019;44(6):483\u20134. https:\/\/doi.org\/10.1097\/RLU.0000000000002508.","journal-title":"Clin Nucl Med"}],"container-title":["EJNMMI Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13550-026-01433-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-026-01433-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-026-01433-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T18:36:10Z","timestamp":1778092570000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13550-026-01433-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,22]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1433"],"URL":"https:\/\/doi.org\/10.1186\/s13550-026-01433-9","relation":{},"ISSN":["2191-219X"],"issn-type":[{"value":"2191-219X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,22]]},"assertion":[{"value":"12 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The need for ethics approval was waived by the local ethics committee given the nature of the retrospective study involving a single anonymized case.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Consent to publish was obtained from the patient. All procedures were discussed with the patient and he gave his full consent, which was digitally archived in the electronic medical records system of the hospital.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Co-author ML acts as a consultant (paid to the institution) for Boston Scientifc, Terumo, Quirem Medical, Novartis, NRG Pallas, Oncosil, and Becton and Dickinson and receives research support from Boston Scientifc, Terumo, Quirem Medical, SOFIE and Novartis. The other authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"72"}}